Psychedelic Funding Update: Q3 2025
Q3 2025 saw just over $120M flow into psychedelics companies, with atai Life Sciences, Reunion Neuroscience, and Sensorium Therapeutics leading the way. Explore key trends, public vs. private dynamics, and how the markets are reacting to trial and regulatory news in our Q3 roundup.